NFKB1 and Miyoshi myopathy: PPFIA binding protein 1 (PPFIBP1), highly expressed in MM plasma cells, enhances chemoresistance to bortezomib treatment by stabilizing p65, promoting its cyto-nuclear translocation, and activating the NF-κB signaling pathway [152].